Associated Papers
Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction.
Deb I et al.
Journal of Neurochemistry, 2010
[Are polymorphisms in the mu-opioid receptor important for opioid therapy?].
Lötsch J et al.
Schmerz (berlin, Germany), 2005
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.
Goldman D et al.
Journal of Studies on Alcohol. Supplement, 2005
Clinical response to morphine in cancer patients and genetic variation in candidate genes.
Ross JR et al.
The Pharmacogenomics Journal, 2005
Gene polymorphisms of the mu opioid receptor in methamphetamine abusers.
Ide S et al.
Annals of the New York Academy of Sciences, 2004
Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor.
Beyer A et al.
Journal of Neurochemistry, 2004
Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?
Lötsch J et al.
Anesthesiology, 2002
A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans.
Höllt V
Pharmacogenetics, 2002
Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction.
LaForge KS et al.
American Journal of Medical Genetics, 2000
Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers.
Lötsch J et al.
The Pharmacogenomics Journal, 0
Select a paper to view details